United Kingdom, 25 February 2026 — The UK medical device registration landscape is the MHRA guidance updated in February 2026: “Register medical devices to place on the market.” The document outlines a significant shift in how devices are registered, paid for, and maintained in Great Britain and Northern Ireland. Specifically, the MHRA is moving away from its legacy one-off registration system toward a sustainable, annual model designed to fund enhanced post-market surveillance and patient safety. For manufacturers, this means a critical deadline of March 30, 2026, to clean up existing data, including the accurate use of the global medical device nomenclature code, or face permanent account closure. Manufacturers must also ensure they appoint a UK Responsible Person to comply with the new regulatory requirements.
UK MEDICAL DEVICE REGISTRATION: THE 2026 SHIFT FROM ONE-OFF TO ANNUAL FEES
Currently, manufacturers pay a one-time fee of £261 per registration application. Starting April 1, 2026, this will be replaced by a recurring annual fee structure.
The fee is not per device, but rather based on the GMDN Level 2 Category. If a manufacturer has multiple products that fall within the same GMDN Level 2 family, they pay a single annual fee for that entire category.
- Cost Estimate: The MHRA anticipates a unit cost of approximately £300 per year, per GMDN Level 2 category.
- Pro-Rata Billing: New devices added mid-year will incur a pro-rata fee for the remaining months of the annual cycle.
- Payment Window: Invoices must be paid within 90 days of issue via the (Device Online Registration System) DORS portal. Failure to pay will lead to account suspension and removal from the public register.
UK MEDICAL DEVICE REGISTRATION: THE 'CLEAN-UP' DEADLINE – MARCH 30, 2026
The MHRA has designated March 30, 2026, as the final day of the current UK medical device registration framework. This is a “hard” deadline with significant consequences:
- Account Closure: Any account that remains suspended at 17:00 on March 30 will be permanently closed.
- Nomenclature Purge: The MHRA will delete all invalid “pseudo” GMDN codes by March 31, 2026. Manufacturers must ensure their devices are mapped to valid, current GMDN terms to maintain registration.
- System Downtime: The DORS portal will be offline for maintenance and transition from the evening of March 30 until April 1, 2026.
KEY REGULATORY REQUIREMENTS FOR MANUFACTURERS
Beyond fees, the updated guidance clarifies the legal obligations for manufacturers and their representatives:
1. The UK Responsible Person (UKRP)
Manufacturers based outside the UK must appoint a single UKRP. This relationship must now be governed by a formal Letter of Designation a legal contract that explicitly lists the (UK Responsible Person) UKRP’s mandatory tasks and confirms their status as the exclusive representative for the manufacturer’s devices in the UK.
2. Northern Ireland and EUDAMED
The Northern Ireland market continues to align with EU regulations. From May 28, 2026, all non-custom-made medical devices must be registered in the European Database on Medical Devices (EUDAMED) before they can be placed on the Northern Ireland market. From this date, MHRA registration will no longer be required for these specific devices in Northern Ireland.
3. Public Transparency (PARD)
Public visibility is increasing. From February 23, 2026, the Public Access Registration Database (PARD) began displaying medical device brand and trade names. This move toward transparency ensures that patients and healthcare providers can easily verify the registration status of the specific products they use.
STRATEGIC IMPACT ON MANUFACTURERS
The transition to an annual fee model marks the MHRA’s shift to a lifecycle funding model. While this introduces a recurring cost, it also offers administrative benefits. From April 2026, the MHRA will remove fees for administrative updates, such as:
- Changes to company name or address.
- Uploading new Letters of Designation for UKRPs.
- Managing administrative contacts within the DORS portal.
CONCLUSIONS
The 2026 MHRA updates represent a modernization of the UK regulatory framework, prioritizing data integrity and financial sustainability. Manufacturers must act before the March 30 deadline to audit their GMDN codes, finalize their UK Responsible Person (UKRP) contracts, and budget for the new annual fee structure. By ensuring “clean” data now, manufacturers can avoid the risk of permanent account closure and benefit from the streamlined administrative processes coming in April. Strategic regulatory support is essential to ensure device portfolios are correctly categorized to minimize costs while maintaining full compliance with the UK Medical Device Registration.